Introduction
============

Hypertension represents today a major public concern. In fact, it affects more than 20% of the adult population in Western countries and about a billion people worldwide ([@b9]; [@b26]). The presence of high blood pressure levels doubles the risk of ischemic heart disease and increases by four-fold incidence of stroke ([@b36]; [@b24]). On the other hand, treatment of hypertension reduces by approximately 40% stroke incidence and by about 14% coronary events ([@b6]). In spite of these evident benefits, only 20% of hypertensive patients receive an adequate treatment to keep blood pressure within the recommended threshold of normality ([@b19]; [@b40]). Together with the other modifiable cardiovascular risk factor, such as hyperglicemia, hypercholesterolemia, smoking and obesity, hypertension heavily contributes to the global cardiovascular burden of morbidity and mortality, as well as to increase individual absolute cardiovascular risk ([@b22]). In this view, modern strategies of cardiovascular prevention should consider a more comprehensive evaluation of risk factor profile in the individual patient ([@b13]; [@b41]; [@b1]).

The clustering of cardiovascular risk factors in hypertensive patients is indeed an extremely frequent observation in both epidemiological studies and clinical practice, and less than 20% of hypertensive patients have no associated risk factors, whereas the remaining 80% have one or more associated risk factors ([@b22]). As addressed in the most recent European Guidelines on hypertension ([@b13]), the concomitant presence of risk factors in hypertensive patients translates in progressively higher absolute cardiovascular risk, as clearly demonstrated about 15 years ago in the Framingham Heart Study ([@b5]). Depending upon the co-existence of none, one, two or more risk factors or diabetes, the level of added risk rises from low to moderate or high risk, as represented in [Figure 1](#fig1){ref-type="fig"}.
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In this view, as the benefits of reducing blood pressure are proportional to the levels of risk, in high-risk hypertensive patients a tighter control of blood pressure levels is recommended, and will result in a progressively greater benefit. In specific conditions, such as in the presence of concomitant diabetes, lower blood pressure targets are recommended to ensure a larger impact on outcomes, as it has been demonstrated in the United Kingdom Prospective Diabetes Study (UKPDS) ([@b35]).

Recommendations derived from guidelines ([@b13]) and recent observations from large international trials in hypertension ([@b42]; [@b14]) clearly indicate that a prompt and tight control of blood pressure may reduce cardiovascular events in high-risk subjects. In this view, patients with hypertension and multiple concomitant risk factors, as those included in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) study ([@b21]), deserve closer clinical observation and more prompt and aggressive therapeutic control of blood pressure levels aiming at the achievement of target levels of or below. In these patients multiple (two up to four) antihypertensive agents are often required to achieve the recommended targets. However, the achievement of blood pressure targets is difficult in such patients, and therefore, in order to adequately reduce the level of risk, other therapeutic strategies aimed at reducing the influence of concomitant risk factors (eg, lipid-lowering agents or aspirin) are helpful ([@b20]; [@b31]; [@b17]).

On the basis of these evidence, modern strategies of cardiovascular prevention in hypertensive patients should move from a single risk factor-based approach (eg, focusing on blood pressure) toward a more comprehensive evaluation and management of risk factor profile in the individual patient ([@b3]; [@b38]). In other words, it is important to adopt a more thorough approach aimed at reducing global cardiovascular risk. The decision to treat a patient should be based on the level of global risk, rather than on the level of a single risk factor. The decision about which risk factor, or factors, to treat should be also based primarily on the level of risk: the higher the absolute risk, the more intensive and extensive the treatment should be ([@b3]; [@b38]). This approach starts and ends with the patient's global risk rather than on the basis of the level of a single risk factor.

Modern view of multiple risk management
=======================================

Over the past two decades, observational studies have consistently demonstrated a strong and direct correlation between cardiovascular morbidity and mortality across the whole blood pressure spectrum, with no evidence of a threshold down to as low as 115/75 mmHg ([@b9]; [@b26]). For instance, the Framingham Heart Study showed that even slight elevations in blood pressure levels to the prehypertensive threshold (120--139/80--89 mmHg) is associated with a doubling of the incidence of cardiovascular events versus "normal" blood pressure levels (\<120/80 mmHg) ([@b37]). Consistent evidence supporting a continuous relationship between blood pressure and cardiovascular risk can be derived from other large epidemiological studies and databases ([@b32]; [@b42]). Moreover, nonhypertensive individuals with multiple risk factors or a history of cardiovascular disease are often at higher absolute risk of cardiovascular and renal events than hypertensive patients with few or no other additive risk factors ([@b10]).

As a consequence, guidelines have started to acknowledge the concept that other factors, besides high blood pressure levels, may further contribute to determine global cardiovascular risk profile of an individual patient. Although this process is still slow and incomplete, and in some representative sets of guidelines, such as in those issued in 2003 by Joint National Committee (JNC) VII ([@b8]), this is not properly addressed in criteria for diagnosis and classification of essential hypertension.

Historically, therapeutic intervention thresholds for the treatment of cardiovascular risk factors, such as high blood pressure, blood cholesterol and glucose levels, have been based on different arbitrary threshold of each individual risk factor, which have been issued in different sets of guideline. Accordingly, physicians frequently persist to focus on the treatment of high blood pressure or cholesterol levels, rather than on the prevention of high blood pressure or high cholesterol-related cardiovascular disease. Because risk factors cluster in individuals ([@b22]), and there is a graded and continuous association between the sum of risk factors and overall cardiovascular risk ([@b32]; [@b2]), the contemporary approach to treatment should be unequivocally based on the assessment of the threshold, at least for cholesterol and blood pressure, based on the calculation of estimated coronary ([@b22]; [@b10]) or cardiovascular (coronary plus stroke) ([@b13], [@b15], [@b16]) risk over a defined (usually 5 or 10 years) period.

Evidence derived from large studies demonstrated that blood pressure lowering and lipid lowering agents may substantially reduce the risk of coronary or major cardiovascular events in a broad range of otherwise healthy subjects at high-risk profile, as well as in hypertensive or hypercholesterolemic patients at different thresholds of absolute risk (Daholf et al 2002, 2005; [@b7]; [@b21]; [@b23]). The absolute benefits of these regimens for such patients are substantially greater than those achieved in patients with uncomplicated hypertension or hypercholesterolemia. In this regard, even small reductions in blood pressure levels, as well as for any other traditional risk factor, may generate significant reduction of absolute risk in high-risk patients. As schematically shown in [Figure 2](#fig2){ref-type="fig"}, the treatment of multiple risk factors (eg, blood pressure and blood cholesterol) results in additive benefit, that clearly exceed the advantage of reducing aggressively one single risk factor (for instance, normalizing blood pressure).
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Although arguments persist about the degree to which these effects relate to drug-specific properties, data suggest that the size of the risk factor reduction achieved is a more important determinant of outcome than the choice of drug, especially in high-risk individuals ([@b2]). In this type of patients, clinical outcomes trials, including the Perindopril pROtection aGainst REcurrent Stroke Study (PROGRESS) ([@b33]), the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT) ([@b4]), and the VALUE studies ([@b21]), support the concept that "lower is better" for blood pressure. In addition, evidence derived from international, randomized, controlled trials, such as the Lipid-Lowering Arm of the Anglo- Scandinavian Cardiac Outcomes Trial (ASCOT-LLA) ([@b31]), the Pravastatin or Atorvastatin Evaluation and Infection Therapy--Thrombolysis in Myocardial Infarction 22 (PROVE IT--TIMI 22) trial ([@b7]) and more recently the Treating to New Targets (TNT) trial ([@b23]), strongly indicate that in hypertensive patients with very high cardiovascular risk an aggressive therapeutic approach aimed to lower the serum cholesterol concentrations with higher doses of statins rather than those commonly used in the clinical practice, significantly reduced the incidence of cardiovascular mortality and major cardiovascular events respect to conventional treatment. However, most patients worldwide are neither being treated effectively, nor achieving optimal blood pressure or cholesterol control ([@b27]; [@b25]), according with recommendations of the recent guidelines ([@b16]; [@b13]).

Global cardiovascular risk assessment
=====================================

As previously discussed, the presence of multiple cardiovascular risk factors rather than high level of any single risk factor in particular is usually the primary determinant of global risk of cardiovascular events in an individual. The absolute risk is the likelihood that a person will have a cardiovascular event over a given period of time (usually 5 to 10 years) ([@b16]). On the other hand, the relative risk is represented by the ratio of the absolute risk of a given patient (or group) to that of a low-risk group ([@b16]). Treatment decisions are based on the likelihood an individual will have a cardiovascular event over a given period of time ([@b16]). This replaces decision-making based on individual risk factor levels. It follows that at a given blood pressure, the risk of cardiovascular events can vary widely depending on the presence or absence of other nonblood pressure-related risk factors. Randomized clinical trials have also shown that in persons with a given blood pressure level, the relative risk reduction with antihypertensive treatment is similar in those with or without other risk factors ([@b3]). Two patients with the same systolic blood pressure may have very different global cardiovascular risk depending on the presence or absence of other risk factors ([@b38]). Their relative treatment benefit is the same, but the absolute risk benefit will be much greater in the higher-risk person.

In whom and when is it appropriate to do risk assessment?
---------------------------------------------------------

As recommended by the most recent guidelines, risk assessments should be provided at the primary care level by health practitioners with appropriate training ([@b16]; [@b10]). Practitioners should be aware of the need to focus on population groups that have a high burden of cardiovascular disease. Accordingly, cardiovascular risk assessments are recommended:

1.  ◦ from the age of 45 years for asymptomatic men without other known risk factors

2.  ◦ from the age of 55 years for asymptomatic women without other known risk factors.

3.  ◦ from the age of 35 years for men with other known cardiovascular risk factors or at high risk of developing diabetes

4.  ◦ from the age of 45 years for women with other known cardiovascular risk factors or at high risk of developing diabetes.

5.  ◦ All those with cardiovascular disease should have comprehensive risk factor measurements to determine the best management approach.

How to perform the risk assessment?
-----------------------------------

In the clinical practice, the evaluation of the patient's individual risk can be facilitated by the use of several tools. The application of risk charts, for instance, provide either advantages (quick and simple means to calculate the global cardiovascular risk; projection of the risk of an individual over time; comprehensible way to explain the risk factor modification concept to patients; etc), and limitations (limited number of risk factors that can be included; physicians should consider other risk factors and qualifiers when estimating individual risk profile; do not replace good clinical judgment about which and how much risk factors should be managed; no magic cut-point in defining classes of risk, as the cardiovascular risk is a continuum).

Risk charts generally identify major modifiable traditional risk factors (cigarette smoking, elevated blood pressure levels, elevated serum Total and LDL Cholesterol levels, low serum HDL Cholesterol levels, Diabetes Mellitus) and major not modifiable risk factors (age, sex, race). Other predisposing risk factors (abdominal obesity, physical inactivity, family history of premature coronary heart disease, psychosocial factors) or conditional risk factors (elevated serum triglycerides, small LDL particles, elevated serum homocysteine, elevated serum lipoprotein(a), C-reactive protein) are usually not considered. While major risk factors are strongly and independently related to increased incidence of major cardiovascular events, such as acute myocardial infarction, ischemic stroke or total cardiovascular mortality, which often represent the primary hard endpoints in the clinical trials, the other risk factors, even though a smaller quantitative contribution in determining the global risk profile and not a well-defined role in the pathogenesis of cardiovascular events, have been demonstrated to be of relevance in the clinical management of individual patients, and often represent direct targets of treatment in the clinical practice, characterizing the so-called secondary endpoints in the clinical trials. In addition, it is of note that the concomitant presence of other not modifiable risk factors, mostly age, represents a condition predisposing the development and enhancing the deleterious effects of concomitant modifiable risk factors.

A large body of risk charts and calculators to assess the coronary or global (coronary and cerebrovascular events) risk in individual patients have been proposed in the last two decades, since the Framingham experience ([@b22]). In this latter regard, the Framingham Score predicts either total coronary heart disease (CHD) (stable and unstable angina pectoris, myocardial infarction and CHD death), or major CHD events (myocardial infarction and CHD death) ([@b22]). However, this estimation of cardiovascular risk implies several limitations. In fact, it derives from old measurements, it does not consider significant differences among other populations, it indicates only an average value of risk (not individual variability), and it does not adequately account for severe abnormalities of risk factors (eg, severe hypercholesterolemia or hypertension or heavy smoking), leading to an underestimation of global cardiovascular risk.

Recently, concerns have been raised about implementation of Framingham Risk Score in European populations Observational studies performed in Italy (2000), Denmark (2002) and Germany (2003) have clearly demonstrated that Framingham risk function overestimates coronary risk in European populations, due to a definition of nonfatal endpoints used in Framingham that is different from than in other cohort studies and clinical trials, and mostly to the objective difficulty in using local data to adjust the model for the use in individual European countries ([@b18]; [@b28]; [@b34]). In view of these evidence, European Society of Cardiology have carried out the Systematic COronary Risk Evaluation (SCORE) project ([@b10]) for the estimation of the 10-year risk of fatal cardiovascular disease in Europe, as reported in [Figure 3](#fig3){ref-type="fig"} (Panel A and B). The SCORE risk predictor system introduces several differences with respect to the Framingham Risk Score. First of all, it considers the total cardiovascular mortality rather than total cardiovascular events as the primary endpoint, including all atherosclerotic deaths (coronary artery diseases and cerebrovascular diseases). Total cardiovascular risk gives a better estimate of individual risk, since noncoronary cardiovascular diseases represent a greater proportion of whole cardiovascular risk in European regions with low coronary artery disease. Secondly, it separates charts for lower (Belgium, France, Greece, Italy, Luxemburg, Spain, Switzerland, Portugal) and higher (United Kingdom, Sweden, Scotland, and other European regions) risk areas of Europe. These charts does not consider different algorithms for diabetic patients, in view of the facts that type 2 diabetes is associated per se with a 2-fold risk for men and 4-fold additive risk for women, determining itself an high-risk profile, as also highlighted in the most recent guidelines ([@b13]).

According to the SCORE, the definition of high total risk for developing a fatal cardiovascular events is represented by: 1) patients with established cardiovascular disease; 2) asymptomatic subjects who have: multiple risk factors resulting in a 10 year risk more than 5% now or if extrapolated to age 60 years, or markedly raised levels of single risk factors; 3) total cholesterol more than 320 mg/dl, LDL cholesterol more than 240 mg/dl, blood pressure more than 180/110 mmHg; 4) diabetes type 2 and diabetes type 1 with microalbuminuria. It is of note that total cardiovascular risk may also be higher than indicated in the chart in the following settings: a) in subjects approach the next age category; b) in asymptomatic subjects with preclinical evidence of atherosclerosis (eg, computerized tomography or ultrasonography); c) in subjects with a strong family history of premature cardiovascular disease; d) in subjects with low HDL cholesterol levels, with raised triglyceride levels, with impaired glucose tolerance, and with raised levels of C-reactive protein, homocysteine, apolipoprotein B or Lp(a); e) in obese and sedentary subjects.
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After risk assessment: How to manage global risk?
=================================================

Strict application of these recommendations should never replace the good clinical practice and personal experience of physicians, which should base their decisions on the evidence-based medicine, rather than simple application of risk calculator. In fact, most hypertension-related deaths come from patients with only modestly raised blood pressure, simply because they are so much more numerous. The same principles apply both to cholesterol and to total risk.

Multiple drug regimens to control risk are generally difficult to maintain and may be less practical and effective than an integrated approach to multiple risk targets by mixing antihypertensive drugs and other risk-lowering interventions, such as lipid-lowering agents and aspirin.

Within the therapeutic strategy of the management of hypertension, especially in patients with concomitant risk factors, target organ damage or co-morbidities (left ventricular hypertrophy, microalbuminuria, atherosclerosis, left ventricular dysfunction, ischemic heart or cerebral disease and nephropathy), there is growing evidence supporting the use of newer antihypertensive drugs, such as those inhibiting the renin-angiotensin system (ACE Inhibitors or Angiotensin Receptor Blockers \[ARB\]) ([@b30]). The beneficial effects of antihypertensive regimens, mostly based on ARBs, do not seem to be exclusively linked to the documented blood pressure lowering effect of these compounds, and therefore they have been at least partially attributed to other mechanisms ([@b39]). In addition, clinical research from prospective trials strongly support the benefit of using a lipid-lowering regimen in hypertensive patients, including those with other cardiovascular risk factors, even in patients who might not be candidates for such treatment, according to current guidelines on lipid-lowering treatment ([@b39]).

Conclusions
===========

In conclusion, it is more appropriate to consider the global risk in arriving at decisions regarding clinical management of high-risk patients. In the modern strategies aimed at reducing global burden of cardiovascular disease, the overall risk reduction should represent the goal in the clinical practice, which is best achieved by establishing global risk profile, identifying modifiable components of risk, and then starting the most effective and tolerable therapeutic strategy. Recent evidence strongly support a more comprehensive strategy aimed at reducing all the components of the global cardiovascular risk rather than the level of each risk factor. In the clinical practice, this approach has been demonstrated to significantly reduce the global burden of disease in hypertensive patients at high risk ([@b29]). In this regard, it is important to define the global cardiovascular risk threshold to manage patients at high-risk, rather than to focus on the high level of a single risk factor, for achieving effective control of cardiovascular risk profile and reducing cardiovascular morbidity and mortality in the general population, as well as in hypertensive population.
